Sector News

Air Liquide acquires healthcare businesses in Belgium and the Netherlands

April 14, 2024
Life sciences

Air Liquide S.A. (Paris) is continuing its development with the acquisition of Homecare activities in Belgium and the Netherlands. With this operation, the Group broadens its presence and offer in these countries. Worldwide Air Liquide already supports 2 million people at home living with a chronic disease and has made Home Healthcare activities one of its strategic development priorities.

The two entities acquired in Belgium and the Netherlands support 10,000 patients living with respiratory insufficiency, sleep apnea syndrome or requiring infusion or nutrition treatments. With a turnover of more than €10 million in 2023, they are supported by around fifty employees who have joined the Air Liquide Group.

VitalAire, Air Liquide’s international Home Healthcare brand, is already present in Belgium, Luxembourg and the Netherlands. Drawing on its medico-technical expertise, its experience in personalized support for patients and in the development of associated digital services, Air Liquide, through this acquisition, is strengthening its presence and completing its infusion offer in these two countries.

The geographic and therapeutic complementarity of the acquired entities, combined with the professionalism and the operational excellence of the Air Liquide Group’s teams, will facilitate the development of care plans adapted to patients’ needs and profiles.

Diana Schillag, member of Air Liquide’s Executive Committee in charge of Healthcare, Sustainable Development and Procurement, stated: “We are delighted to strengthen our position in those growing markets and to welcome these new patients and employees to Air Liquide. As a major player in Home Healthcare throughout the world, our ambition is to improve the quality of life of patients to best meet their needs at the lowest cost to society, thereby contributing to more efficient and sustainable healthcare systems.”

By Mary Bailey


comments closed

Related News

May 17, 2024

With new partnership, Galapagos takes decentralized CAR-T manufacturing quest nationwide

Life sciences

Though Galapagos has undergone plenty of staff shake-ups and strategy revamps in recent years, the company is sticking strong to the CAR-T pivot first unveiled by CEO Paul Stoffels, M.D., following his arrival at the biotech from Johnson & Johnson in early 2022.

May 17, 2024

Sanofi invests €1 Billion to boost drug manufacturing in France

Life sciences

The new investment is expected to create more than 500 jobs and significantly strengthen France’s ability to control the production of essential medicines from start to finish, the company stated. According to Sanofi, this plan increases the amount Sanofi has committed to major projects in France since the Covid-19 pandemic to over €3.5 billion.

May 17, 2024

Lonza, busy with capacity upgrades and exec turnover, hints at CDMO industry rebound

Life sciences

A tough biotech funding environment and a downturn in COVID-related contracts has weighed heavily on CDMOs of all stripes in recent years. Now, with a new CEO waiting in the wings, Swiss manufacturing juggernaut Lonza is attempting to reassure the market that an industry stabilization is on the horizon.

How can we help you?

We're easy to reach